relmada - Search News

Relmada acquires neurosteroid from Asarina

Relmada acquires Tourette’s therapy rights from Asarina

Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma. Sepranolone is a neurosteroid being developed as a potential treatment for Tourette's syndrome (TS) and other compulsive disorders.

Business Insider · 2d

Relmada Therapeutics acquires Sepranolone from Asarina Pharma

Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed

Investing.com on MSN · 2d

Relmada acquires new Tourette syndrome treatment asset

CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid,

The Pharma Letter · 1d

Relmada in-licenses Tourette syndrome drug from Asarina

US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from Sweden’s Asarina Pharma, being developed for the potential treatment of Tourette syndrome (TS) and other compulsive disorders.

Business Insider · 2d

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from

FierceBiotech1d

After phase 3 miss, Relmada picks up midstage Tourette’s asset from Swedish biotech

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

Nasdaq2d

Relmada Therapeutics Acquires Sepranolone from Asarina Pharma for Tourette Syndrome Treatment Development

Relmada Therapeutics has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid developed for treating Tourette syndrome (TS) and related compulsive disorders, from Asarina Pharma ...

5don MSN

RLMD stock touches 52-week low at $0.34 amid sharp annual decline

In a challenging year for Relmada Therapeutics (NASDAQ:RLMD), the company's stock has plummeted to a 52-week low, trading at just $0.34. According to InvestingPro data, the company maintains a strong ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Relmada acquires neurosteroid from Asarina

Trending now